Cadila Healthcare’s US arm -- Zydus Pharmaceuticals USA Inc -- is recalling 44,800 bottles of antidepressant Paroxetine tablets from the American market in the strength of 30 mg. The reason for the recall is the presence of foreign tablets. The voluntary ongoing nationwide recall is a class II recall.
According to the USFDA, a class II recall is initiated in a ‘situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote’.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
